prediction model for gene mutation5

^[1]^[2]^[3]^[4]

Indications

↑ Kastrinos F, Uno H, Ukaegbu C et al Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 1;35(19):2165-2172. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28489507 Free PMC article.
↑ Adviento B, Conner M, Sarkisian A et al Feasibility of Utilizing PREMM Score for Lynch Syndrome Identification in an Urban, Minority Patient Population. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211020973. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34053368 Free PMC article.
↑ Mittendorf KF, Ukaegbu C, Gilmore MJ et al Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5TM) for lynch syndrome risk assessment in a diverse population. Fam Cancer. 2021 Mar 23:10.1007/s10689-021-00243-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33754278
↑ Goverde A, Spaander MCW, Nieboer D et al Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers. Fam Cancer. 2018 Jul;17(3):361-370. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28933000 Free PMC article